Hypoxia/reoxygenation: A dynamic regulator of lysyl oxidase-facilitated breast cancer migration

被引:68
|
作者
Postovit, Lynne-Marie [1 ]
Abbott, Daniel E. [2 ]
Payne, Stacey L. [1 ]
Wheaton, William W. [1 ]
Margaryan, Naira V. [1 ]
Sullivan, Richard [3 ]
Jansen, Matthias K. [4 ]
Csiszar, Katalin [4 ]
Hendrix, Mary J. C. [1 ]
Kirschmann, Dawn A. [1 ]
机构
[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Childrens Mem Res Ctr, Chicago, IL 60614 USA
[2] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60614 USA
[3] Queens Univ, Dept Anat & Cell Biol, Kingston, ON, Canada
[4] Univ Hawaii, John A Burns Sch Med, Cardiovasc Res Ctr, Honolulu, HI 96822 USA
关键词
motility; breast cancer; lysyl oxidase; hypoxia; reoxygenation;
D O I
10.1002/jcb.21517
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fluctuating oxygen levels characterize the microenvironment of many cancers and tumor hypoxia is associated with increased invasion and metastatic potential concomitant with a poor prognosis. Similarly, the expression of lysyl oxidase (LOX) in breast cancer facilitates tumor cell migration and is associated with estrogen receptor negative status and reduced patient survival. Here we demonstrate that hypoxia/reoxygenation drives poorly invasive breastcancer cells toward a more aggressive phenotype by up-regulating LOX expression and catalytic activity. Specifically, hypoxia markedly increased LOX protein expression; however, catalytic activity (beta-aminopropionitrile inhibitable hydrogen peroxide production) was significantly reduced under hypoxic conditions. Moreover, poorly invasive breast cancer cells displayed a marked increase in LOX-dependent FAK/Src activation and cell migration following hypoxia/reoxygenation, but not in response to hypoxia alone. Furthermore, LOX expression is only partially dependent on hypoxia inducible factor-1 (HIF-1 alpha) in poorly invasive breast cancer cells, as hypoxia mimetics and overexpression of HIF-1 alpha could not upregulate LOX expression to the levels observed under hypoxia. Clinically, LOX expression positively correlates with tumor progression and co-localization with hypoxic regions (defined by HIF-1 alpha expression) in ductal carcinoma in situ and invasive ductal carcinoma primary tumors. However, positive correlation is lost in metastatic tumors, suggesting that LOX expression is independent of a hypoxic environment at later stages of tumor progression. This work demonstrates that both hypoxia and reoxygenation are necessary for LOX catalytic activity which facilitates breast cancer cell migration through a hydrogen peroxide-mediated mechanism; thereby illuminating a potentially novel mechanism by which poorly invasive cancer cells can obtain metastatic competency.
引用
收藏
页码:1369 / 1378
页数:10
相关论文
共 50 条
  • [21] Lysyl oxidase is associated with the epithelial-mesenchymal transition of gastric cancer cells in hypoxia
    Kasashima, Hiroaki
    Yashiro, Masakazu
    Kinoshita, Haruhito
    Fukuoka, Tatsunari
    Morisaki, Tamami
    Masuda, Go
    Sakurai, Katsunobu
    Kubo, Naoshi
    Ohira, Masaichi
    Hirakawa, Kosei
    GASTRIC CANCER, 2016, 19 (02) : 431 - 442
  • [22] Inhibition of lysyl oxidase in breast cancer cells by small-molecule inhibitors
    Johnston, Kathryn
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [23] Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer
    De Vita, Alessandro
    Liverani, Chiara
    Molinaro, Roberto
    Martinez, Jonathan O.
    Hartman, Kelly A.
    Spadazzi, Chiara
    Miserocchi, Giacomo
    Taraballi, Francesca
    Evangelopoulos, Michael
    Pieri, Federica
    Bongiovanni, Alberto
    Mercatali, Laura
    Tasciotti, Ennio
    Ibrahim, Toni
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [24] Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer
    Alessandro De Vita
    Chiara Liverani
    Roberto Molinaro
    Jonathan O. Martinez
    Kelly A. Hartman
    Chiara Spadazzi
    Giacomo Miserocchi
    Francesca Taraballi
    Michael Evangelopoulos
    Federica Pieri
    Alberto Bongiovanni
    Laura Mercatali
    Ennio Tasciotti
    Toni Ibrahim
    Scientific Reports, 11
  • [25] Could the "Stiff Rim Sign" Be an Indicator of Lysyl Oxidase Activity in Breast Cancer?
    Kayadibi, Yasemin
    Kilic, Fahrettin
    Karatas, Omer Faruk
    Ilvan, Sennur
    Esmerer, Emel Ure
    Kayadibi, Turgut
    Yilmaz, Mehmet Halit
    IRANIAN JOURNAL OF RADIOLOGY, 2019, 16 (03)
  • [26] Association between lysyl oxidase and fibrotic focus in relation with inflammation in breast cancer
    Jeong, Young Ju
    Park, Sung Hwan
    Mun, Sung Hee
    Kwak, Sang Gyu
    Lee, Sun-Jae
    Oh, Hoon Kyu
    ONCOLOGY LETTERS, 2018, 15 (02) : 2431 - 2440
  • [27] Lysyl oxidase interacts with hormone placental lactogen and synergistically promotes breast epithelial cell proliferation and migration
    Polgar, Noemi
    Fogelgren, Ben
    Shipley, J. Michael
    Csiszar, Katalin
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (05) : 3262 - 3272
  • [28] Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer
    Ozge Saatci
    Aysegul Kaymak
    Umar Raza
    Pelin G. Ersan
    Ozge Akbulut
    Carolyn E. Banister
    Vitali Sikirzhytski
    Unal Metin Tokat
    Gamze Aykut
    Suhail A. Ansari
    Hayriye Tatli Dogan
    Mehmet Dogan
    Pouria Jandaghi
    Aynur Isik
    Fatma Gundogdu
    Kemal Kosemehmetoglu
    Omer Dizdar
    Sercan Aksoy
    Aytekin Akyol
    Aysegul Uner
    Phillip J. Buckhaults
    Yasser Riazalhosseini
    Ozgur Sahin
    Nature Communications, 11
  • [29] The interaction of lysyl oxidase with the placental lactogen hormone and its potential role in breast cancer
    Polgar, Noemi
    Fogelgren, Ben
    Csiszar, Katalin
    CANCER RESEARCH, 2006, 66 (08)
  • [30] Inhibition of lysyl oxidase expression by dextran sulfate affects invasion and migration of gastric cancer cells
    Xu, Yuanyi
    Wang, Xiaofei
    Huang, Yunning
    Ma, Yanmei
    Jin, Xiu
    Wang, Honghong
    Wang, Juan
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2018, 42 (05) : 2737 - 2749